Glioblastomas with oligodendroglial component have the same clinical phenotype as classical glioblastomas (original) (raw)

2013, British Journal of Neurosurgery

Introduction: Glioblastomas are the commonest primary brain tumour and is considered one of the most heterogeneous tumour types. The introduction of a glioblastoma with oligodendroglial component (GBM+O) in the latest WHO Classification of Tumours of the Central Nervous System 1 was to help with this. There has been conflicting evidence as to whether this tumour conferred a better prognosis than classical glioblastoma (GBM). The aim of this study was to study the clinical phenotype of these GBM+O tumours and compare it to the classical GBM. Materials and Methods: All patients with histological evidence of a glioblastoma between 1 st January 2007 and 31 st January 2011 were identified from the Neuropathology Database. Clinical and radiological details were obtained for all patients. The overall survival of patients who were treated with chemoradiotherapy were obtained and the GBM+O cohort compared to the classical GBM cohort. Results: 396 patients with newly diagnosed glioblastomas were identified, 294 (74.2%) were classical GBM and 102 (25.6%) GBM+O. The two cohorts presented at a similar age (61.1 years GBM+O vs. 63.2 years GBM; P = 0.09) and were matched for sex and side of the tumour. GBM+O were more likely to be located in the frontal lobes (38.2% for GBM+O vs. 27.2% for GBM: P = 0.04). In the group that were treated with chemoradiotherapy the overall survival was similar (median survival GBM+O 361 days vs. 379 days GBM; Log Rank 0.61, P = 0.43). Conclusion: The presence of an oligodendroglial component does not confer any improvement in survival and has a similar clinical phenotype to classical GBMs.

Sign up for access to the world's latest research.

checkGet notified about relevant papers

checkSave papers to use in your research

checkJoin the discussion with peers

checkTrack your impact